Bayer HealthCare

Bayer HealthCare of Berlin has entered into a strategic agreement to transfer its hematological oncology portfolio to Genzyme Corp. of Cambridge, Mass. This includes granting the American company exclusive worldwide licenses for several of the products in the portfolio. In return, the German company will receive milestone payments and royalties, which could add up to as much as $650 million.





LATEST NEWS

• Exail Signs LLNL Contract, Partners with Eelume
  Apr 26, 2024
• Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
  Apr 26, 2024
• Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
  Apr 25, 2024
• DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
  Apr 25, 2024
• Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
  Apr 24, 2024
• One-Step Hologram Generation Speeds 3D Display Creation
  Apr 24, 2024
• Innovation Award Winners for Laser Technology Honored in Aachen
  Apr 23, 2024
• Intech 2024: AI Arrives on the Shop Floor
  Apr 22, 2024